- Home
- NRIX
as of 12-05-2025 3:45pm EST
$18.20
+$0.18
+1.00%
Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies.
Chart Type:
Time Range:
| Founded: | 2009 | Country: | United States |
| Employees: | N/A | City: | SAN FRANCISCO |
| Market Cap: | 1.7B | IPO Year: | 2020 |
| Target Price: | $26.50 | AVG Volume (30 days): | 1.6M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 14 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.97 | EPS Growth: | N/A |
| 52 Week Low/High: | $8.18 - $22.95 | Next Earning Date: | 01-27-2026 |
| Revenue: | $83,687,000 | Revenue Growth: | 48.32% |
| Revenue Growth (this year): | 58.38% | Revenue Growth (next year): | -34.06% |
AI-Powered NRIX Daily Prediction
Machine learning model trained on 25+ technical indicators
Updated 3 days ago
AI Recommendation
hold
Model Accuracy: 74.83%
74.83%
Confidence
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Nurix Therapeutics Inc. Common stock (NRIX)
Ring Christine
Sell
Chief Legal Officer
NRIX Nov 24, 2025
Avg Cost/Share
$17.07
Shares
37,600
Total Value
$641,696.64
Owned After
50,897
SEC Form 4
van Houte Hans
Sell
Chief Financial Officer
NRIX Nov 3, 2025
Avg Cost/Share
$12.56
Shares
6,284
Total Value
$78,931.44
Owned After
37,592
SEC Form 4
van Houte Hans
Sell
Chief Financial Officer
NRIX Oct 30, 2025
Avg Cost/Share
$12.80
Shares
3,130
Total Value
$40,053.67
Owned After
37,592
SEC Form 4
Hansen Gwenn
Sell
Chief Scientific Officer
NRIX Oct 30, 2025
Avg Cost/Share
$12.80
Shares
4,087
Total Value
$52,300.11
Owned After
76,751
SEC Form 4
Ring Christine
Sell
Chief Legal Officer
NRIX Oct 30, 2025
Avg Cost/Share
$12.80
Shares
3,644
Total Value
$46,631.17
Owned After
50,897
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Ring Christine | NRIX | Chief Legal Officer | Nov 24, 2025 | Sell | $17.07 | 37,600 | $641,696.64 | 50,897 | |
| van Houte Hans | NRIX | Chief Financial Officer | Nov 3, 2025 | Sell | $12.56 | 6,284 | $78,931.44 | 37,592 | |
| van Houte Hans | NRIX | Chief Financial Officer | Oct 30, 2025 | Sell | $12.80 | 3,130 | $40,053.67 | 37,592 | |
| Hansen Gwenn | NRIX | Chief Scientific Officer | Oct 30, 2025 | Sell | $12.80 | 4,087 | $52,300.11 | 76,751 | |
| Ring Christine | NRIX | Chief Legal Officer | Oct 30, 2025 | Sell | $12.80 | 3,644 | $46,631.17 | 50,897 |
Latest Nurix Therapeutics Inc. Common stock News
NRIX Breaking Stock News: Dive into NRIX Ticker-Specific Updates for Smart Investing
Compare NRIX vs Leading Stocks
See how NRIX stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "NRIX Nurix Therapeutics Inc. Common stock - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.